Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- JCR Completes Patient Enrolment in Japan PIII Study for Hunter Syndrome Treatment
January 7, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
- Kyorin, Hebrew University Link Arms in Respiratory Drug Development
December 28, 2018
- Ono Files Heart Failure Drug Ivabradine in Japan
December 28, 2018
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
- Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
- Xofluza Most Heavily Promoted Drug for GP in October: Anterio
December 27, 2018
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
- Japan Vaccine to Transfer Business to Daiichi Sankyo, GSK in April
December 27, 2018
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Sumitomo Dainippon to Merge Authorized Generic Units
December 26, 2018
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
- Fujifilm, MIT Launch Research Project on Oligonucleotide DDS
December 26, 2018
- INCJ Makes Further Investment in NapaJen Pharma
December 26, 2018
- RaQualia’s Tegoprazan Sublicensed to Vietnam’s Vimedimex
December 26, 2018
- Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…